CRISPR Therapeutics AG (CRSP) Leases (2019 - 2025)
Historic Leases for CRISPR Therapeutics AG (CRSP) over the last 7 years, with Q3 2025 value amounting to $134.7 million.
- CRISPR Therapeutics AG's Leases fell 794.81% to $134.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $134.7 million, marking a year-over-year decrease of 794.81%. This contributed to the annual value of $143.5 million for FY2024, which is 683.93% down from last year.
- Latest data reveals that CRISPR Therapeutics AG reported Leases of $134.7 million as of Q3 2025, which was down 794.81% from $137.6 million recorded in Q2 2025.
- CRISPR Therapeutics AG's 5-year Leases high stood at $179.4 million for Q2 2021, and its period low was $50.1 million during Q1 2021.
- In the last 5 years, CRISPR Therapeutics AG's Leases had a median value of $154.0 million in 2023 and averaged $150.6 million.
- Its Leases has fluctuated over the past 5 years, first surged by 35647.5% in 2021, then tumbled by 1060.68% in 2023.
- Quarter analysis of 5 years shows CRISPR Therapeutics AG's Leases stood at $174.5 million in 2021, then decreased by 10.05% to $156.9 million in 2022, then dropped by 1.87% to $154.0 million in 2023, then dropped by 6.84% to $143.5 million in 2024, then decreased by 6.14% to $134.7 million in 2025.
- Its Leases was $134.7 million in Q3 2025, compared to $137.6 million in Q2 2025 and $140.3 million in Q1 2025.